Skip to main content
aap Implantate AG logo

aap Implantate AG — Investor Relations & Filings

Ticker · AAQ1 ISIN · DE000A3H2101 LEI · 39120001TRQTQ01LPP57 F Manufacturing
Open in API
Filings indexed 854 across all filing types
Latest filing 2017-06-15 Board/Management Inform…
Country DE Germany
Listing F AAQ1

About aap Implantate AG

https://www.aap.de/

aap Implantate AG is a medical technology company that operates as a pure player in the field of traumatology. The company develops, manufactures, and markets implants for the treatment of bone fractures. Its core product is the LOQTEQ® system, a comprehensive portfolio of anatomical plates and screws featuring a patented technology that combines fracture compression with angle-stable locking. This titanium-based system is designed to cover a broad spectrum of indications in upper and lower extremity trauma surgery. In addition to its established product line, aap is developing next-generation platform technologies, including antibacterial silver-coated implants to reduce infection risk and resorbable magnesium implants intended to eliminate the need for secondary removal surgeries.

Recent filings

Filing Released Lang Actions
aap Implantate AG: Supervisory Board extends both Management Board members' contracts prematurely until the end of 2020
Board/Management Information Classification · 100% confidence The document is a news release announcing a specific corporate event: the premature extension of contracts for the Management Board Chairman (CEO) and CFO until the end of 2020. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The keywords 'Management Board members’ contracts prematurely', 'Change of Personnel/Miscellaneous', and the focus on CEO/CFO roles confirm this classification. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A).
2017-06-15 English
aap Implantate AG: First-time shareholder participation in the form of a share buyback following the sale of aap Biomaterials GmbH in financial year 2016
Transaction in Own Shares Classification · 100% confidence The document is a news release announcing that aap Implantate AG will implement a partial distribution of proceeds from a prior sale via a voluntary public share buyback offer. Key phrases include "Share Buyback/Corporate Action," "voluntary public share buyback offer," and details about the offer price and acceptance period. This action directly relates to the company's capital structure management and the distribution of funds to shareholders through the repurchase of its own stock. This aligns precisely with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2017-06-15 English
aap Implantate AG: Public Share Buyback Offer
Regulatory Filings Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 15, 2017, titled 'aap Implantate AG: Public Share Buyback Offer'. It details the resolution by the Management Board to execute a voluntary public share buyback offer for up to 2.25 million shares for a maximum total purchase price of EUR 3.5 million. This action relates directly to the company acquiring its own shares, which aligns precisely with the definition of 'Transaction in Own Shares'. The code for this is POS. Although it is a corporate action, it is specifically about share repurchase, making POS more accurate than CAP (Capital/Financing Update).
2017-06-15 English
aap Implantate AG: Successful start in 2017 with sales and EBITDA increase - 30% sales growth in trauma in Q1/2017
Earnings Release Classification · 100% confidence The document explicitly states it is a 'News Details' announcement from 'aap Implantate AG' concerning 'Quarter Results/Quarterly / Interim Statement' for Q1/2017. It provides key financial highlights (Sales, EBITDA) and an outlook for Q2/2017. This content structure—a brief announcement summarizing period results with key figures and forward guidance, rather than the comprehensive, audited report itself—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on highlights and is distributed via a news service (DGAP). Q1 2017
2017-05-15 English
Quartalsfinanzbericht
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quartalsmitteilung' (Quarterly Statement) for the first quarter of 2017 for aap Implantate AG. It contains detailed financial tables (income statement, cash flow, balance sheet, etc.), management commentary, and analysis of business performance. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-15 German
Q1 statement / Q1 financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a '1st quarter 2017 Quarterly Statement' for aap Implantate AG. It contains detailed financial tables (Sales, EBITDA, EBIT, Cash Flow, Balance Sheet) and a comprehensive 'Business Review' section including a management foreword, earnings position, and operational updates. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2017
2017-05-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.